Regenxbio Inc (NASDAQ:RGNX) price on Friday, July 25, fall -1.86% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $8.96.
A look at the stock’s price movement, the close in the last trading session was $9.13, moving within a range at $8.8615 and $9.22. The beta value (5-Year monthly) was 1.059. Turning to its 52-week performance, $15.36 and $5.03 were the 52-week high and 52-week low respectively. Overall, RGNX moved 4.92% over the past month.
Regenxbio Inc’s market cap currently stands at around $451.48 million, with investors looking forward to this quarter’s earnings report slated for on 2025-May-12.
Analysts have a consensus estimate of 40.87M for the company’s revenue for the quarter, with a low and high estimate of 20M and 142.89M respectively. The average forecast suggests up to a 83.30% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 335.86M, representing a 303.06% jump on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that RGNX is a 50% Buy. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
6 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 6 recommend RGNX as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
RGNX’s current price about 3.70% and -0.26% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 52.82, while 7-day volatility ratio is 6.17% and 6.11% in the 30-day chart. Further, Regenxbio Inc (RGNX) has a beta value of 1.12. Analysts have given the company’s stock an average 52-week price target of $24, forecast between a low of $24 and high of $24. Looking at the price targets, the low is -167.86% off current price level while to achieve the yearly target high, price needs to move -167.86%. Nonetheless, investors will most likely welcome a -167.86% jump to $24 which is the analysts’ median price.
If we refocus on Regenxbio Inc (NASDAQ:RGNX), historical trading data shows that trading volumes averaged 0.55 over the past 10 days and 993.84K over the past 3 months. The company’s latest data on shares outstanding shows there are 50.12 million shares.
The 9.38% of Regenxbio Inc’s shares are in the hands of company insiders while institutional holders own 86.84% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 6.18 million on 2025-07-15, giving us a short ratio of 7.9. The data shows that as of 2025-07-15 short interest in Regenxbio Inc (RGNX) stood at 1489.9999 of shares outstanding, with shares short rising to 5.51 million registered in 2025-06-13. Current price change has pushed the stock -33.63% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the RGNX stock continues to rise going into the next quarter.
